A. Torbeyns

911 total citations
14 papers, 677 citations indexed

About

A. Torbeyns is a scholar working on Psychiatry and Mental health, Rheumatology and Economics and Econometrics. According to data from OpenAlex, A. Torbeyns has authored 14 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Psychiatry and Mental health, 2 papers in Rheumatology and 2 papers in Economics and Econometrics. Recurrent topics in A. Torbeyns's work include Bipolar Disorder and Treatment (6 papers), Schizophrenia research and treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). A. Torbeyns is often cited by papers focused on Bipolar Disorder and Treatment (6 papers), Schizophrenia research and treatment (6 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). A. Torbeyns collaborates with scholars based in United States, Belgium and Netherlands. A. Torbeyns's co-authors include William H. Carson, Robert D. McQuade, Elyse Stock, Г. Ингенито, Teresa A. Pigott, Anutosh Ranjan Saha, Ronald N. Marcus, Raymond Sanchez, Margaretta Nyilas and W. Chrzanowski and has published in prestigious journals such as The British Journal of Psychiatry, Journal of Affective Disorders and Psychopharmacology.

In The Last Decade

A. Torbeyns

14 papers receiving 649 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Torbeyns United States	9	551	90	89	78	69	14	677
Jonathan Thomas United States	10	551 1.0×	84 0.9×	140 1.6×	209 2.7×	31 0.4×	25	820
Maila Majak Sweden	6	581 1.1×	77 0.9×	176 2.0×	172 2.2×	37 0.5×	8	734
Pia Vattulainen Finland	14	542 1.0×	105 1.2×	112 1.3×	86 1.1×	44 0.6×	27	1.0k
Amy Liebeskind United States	5	512 0.9×	73 0.8×	55 0.6×	33 0.4×	79 1.1×	9	678
Ari Jaffe United States	11	305 0.6×	63 0.7×	50 0.6×	38 0.5×	43 0.6×	16	429
Jennifer Kern Sliwa United States	12	334 0.6×	66 0.7×	74 0.8×	69 0.9×	56 0.8×	19	419
Spencer Lourens United States	13	72 0.1×	53 0.6×	71 0.8×	15 0.2×	20 0.3×	29	469
Krishna Talluri United States	12	371 0.7×	79 0.9×	27 0.3×	15 0.2×	113 1.6×	24	521
Nila Bhana New Zealand	8	202 0.4×	85 0.9×	31 0.3×	8 0.1×	50 0.7×	10	871
Adityanjee India	12	232 0.4×	64 0.7×	103 1.2×	50 0.6×	30 0.4×	28	454

Countries citing papers authored by A. Torbeyns

Since Specialization

Citations

This map shows the geographic impact of A. Torbeyns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Torbeyns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Torbeyns more than expected).

Fields of papers citing papers by A. Torbeyns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Torbeyns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Torbeyns. The network helps show where A. Torbeyns may publish in the future.

Co-authorship network of co-authors of A. Torbeyns

This figure shows the co-authorship network connecting the top 25 collaborators of A. Torbeyns. A scholar is included among the top collaborators of A. Torbeyns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Torbeyns. A. Torbeyns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Simon, Teresa A., Benjamin P. Soule, Marc C. Hochberg, et al.. (2019). Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials. ACR Open Rheumatology. 1(4). 251–257. 17 indexed citations

Sulkowski, Mark, S. Flamm, Zeid Kayali, et al.. (2016). Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study). Liver International. 37(6). 836–842. 23 indexed citations

Kao, Jia‐Horng, Jeong Heo, Sang Hoon Ahn, et al.. (2016). All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study. Liver International. 36(10). 1433–1441. 21 indexed citations

Bhagwagar, Zubin, A. Torbeyns, Delphine Hennicken, et al.. (2015). Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology. 35(4). 454–459. 9 indexed citations

Young, Allan H., Dan A. Oren, Adam Lowy, et al.. (2008). Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal of Psychiatry. 194(1). 40–48. 82 indexed citations

Keck, P E, Paul J. Orsulak, Andrew J. Cutler, et al.. (2008). Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. Journal of Affective Disorders. 112(1-3). 36–49. 130 indexed citations

Torbeyns, A., et al.. (2007). P.3.c.005 Aripiprazole monotherapy in acute bipolar I mania: a randomized, placebo- & lithium-controlled study (CN138–135). European Neuropsychopharmacology. 17. S426–S427. 1 indexed citations

Chrzanowski, W., Ronald N. Marcus, A. Torbeyns, Margaretta Nyilas, & Robert D. McQuade. (2006). Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 189(2). 259–266. 105 indexed citations

Pigott, Teresa A., William H. Carson, Anutosh Ranjan Saha, et al.. (2003). Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia. The Journal of Clinical Psychiatry. 64(9). 1048–1056. 255 indexed citations

10.

Casey, Dympna, R. Marcus, William H. Carson, et al.. (2003). Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research. 60(1). 276–276. 7 indexed citations

11.

Stock, Eveline O., S.R. Marder, D. Jody, et al.. (2003). P.2.108 Plasma lipids levels and glycemic control in long-term treatment with aripiprazole. European Neuropsychopharmacology. 13. S327–S327. 8 indexed citations

12.

McQuade, Robert D., et al.. (2002). Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology. 12. 288–288. 10 indexed citations

13.

Benkert, Otto, Alan Wade, Ulla Lepola, et al.. (1999). A multicenter, double-blind comparison of nefazodone and placebo in the treatment of panic disorder. European Neuropsychopharmacology. 9. 250–250. 1 indexed citations

14.

Akritas, Michael G. & A. Torbeyns. (1997). Pearson‐type goodness‐of‐fit tests for regression. Canadian Journal of Statistics. 25(3). 359–374. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact